Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Screener® for Ion Channel Screening will debut at European Lab Automation (ELA) 2012. Instrumentation advances in Ion Channel research have increased experimental throughput by several orders of magnitude. Typically, automated electrophysiology experiments produce gigabytes of raw data, which are severe data analysis bottlenecks. Supporting the latest Ion Channel instrumentation, the new Genedata Screener for Ion Channel Screening overcomes these bottlenecks. It provides a scalable and automated data analysis framework allowing simultaneous analysis on any number of probes.Total data handling and analysis time is reduced by upwards to 95%, and experiment analyses can be completed in less than 1 hour. Genedata Screener for Ion Channel Screening will be demonstrated at ELA, Europe’s largest event for life science automation (CCH – Congress Center Hamburg;
Booth #27 – May 30 - 31).
Platform for Ion Channel Screening
Ion Channels are important targets for therapeutic drugs that address a range of medical conditions from multiple sclerosis to epilepsy and hypertension. Advanced instrumentation for Ion Channel research – such as those used in automated electrophysiology experiments – yield more than 100 million data points on a single-plate experiment. In a given experiment, today’s electrophysiology labs run 3 to 10 plates and record up to 1 billion data points, representing a physical data volume of several gigabytes. While instrumentation has automated measurements, data analysis – for the most part – is mired in repeated manual setups and serial processes. These processes are no longer sustainable as they result in less than optimal quality, diminished expediency, and protracted data analysis times. With Genedata Screener for Ion Channel Screening, scientists can conduct data analysis in minutes and calculate results in seconds – regardless of the number of plates processed. The ability to interactively review and compare raw data and results in a single analysis session enables scientists to improve data quality and optimize results.
With no throughput limitations, Genedata Screener for Ion Channel Screening provides complete screening-specific business logic and functionality with analysis tools for Ion Channel experiments. Inherently interactive, Genedata Screener enables researchers to quickly load, visualize and analyze 100,000s of data points per well from different events and multiple plates. Setting up experiment-specific aggregation rules to analyze regions of interest for several events allows automatic and simultaneous result calculations across all wells.
Additional capabilities include plate quality control with quality metrics, specific plots, advanced filters, masking and correction functionality; replicate analysis; Hit List creation; and Dose-Response Curve fitting. Genedata Screener easily integrates with corporate environments and imports data from leading well/plate instruments such as MD IonWorks® Quattro™, and flow-based instruments including Fluxion IonFlux.
“Ion Channels have become an important and rapidly growing area of research within drug discovery. Limitations in assay configurations and data analyses have been major bottlenecks that we have successfully addressed with Genedata Screener for Ion Channel Screening,” said Dr. Othmar Pfannes, CEO of Genedata. “This analysis platform provides comprehensive Ion Channel screening capabilities that enable researchers to fully explore the scientific depths of experiments and ensure optimal data quality without compromise.”
Genedata Screener for Ion Channel Screening is shipping now and available directly from Genedata.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.